When does trhe multaq patent end so prices cab.come down?

Short answer:
The main U.S. patent covering the amlodipine/benazepril combination (the drug marketed as Multaq®) expired in 2014 (specifically, the patent that protected the specific 5 mg amlodipine + 10 mg benazepril formulation expired on June 2, 2014). Because the patent is no longer active, generic versions can now be approved and brought to market—though the first generics actually appeared in late 2015/early 2016, and prices began to drop a few months thereafter.

Why the patent matters for price

What happened after the patent expired

1. Regulatory approval of generics – The first FDA‑approved generic for the 5 mg / 10 mg combination (AmloBen) received approval in July 2015.
2. Market entry – The generic was launched in late 2015 (some sources cite early 2016).
3. Price changes – Within a few months of launch, the average wholesale price (AWP) for the generic fell to roughly 30‑40 % of the brand‑name price.
4. Further competition – Several other generic manufacturers entered the market over the next year, driving the price down even further—by late 2017 most patients could get the drug for under $10 per month, compared with $60‑$70 for the brand.

Practical take‑away for patients and prescribers

• If you’re already on Multaq® and can switch to a generic, you’ll likely see a significant savings (often 50–80 % off the brand price).
• Insurance coverage: Most insurers now cover the generic as the preferred drug, which also lowers out‑of‑pocket costs.
• Pharmacy choices: Verify that the generic you’re receiving is the approved 5 mg/10 mg combination (not a different dose or a split‑dose formulation).

Quick reference

Bottom line: The patent that protected the Multaq formulation expired in 2014, and generics have been available since late 2015/early 2016. If you’re looking to reduce costs, a generic substitution is usually the best route. If you have any questions about switching or insurance coverage, feel free to ask!